One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Challenges and Opportunities in Establishing Appropriate Intermediate Endpoints Reflecting Patient Benefit: A Roadmap for Research and Clinical Application in Nonmetastatic Prostate Cancer
Sabine D. Brookman-May a b, Marc Buyse c d, Stephen J. Freedland e f, Branko Miladinovic g, Ke Zhang g, Wolfgang P. Fendler h, Felix Feng i j k, Oliver Sartor l, Christopher J. Sweeney m
The Humanitarian Impact of Telesurgery and Remote Surgery in Global Medicine
Vipul Patel a b, Jacques Marescaux c, Marcio Covas Moschovas a b
Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial
Kelly N. Fitzgerald a †, Chung-Han Lee a †, Martin H. Voss a, Maria I. Carlo a, Andrea Knezevic b, Laura Peralta a, Yingbei Chen c, Robert A. Lefkowitz d, Neil J. Shah a, Colette N. Owens a, Deaglan J. McHugh a, David H. Aggen a, Andrew L. Laccetti a, Ritesh R. Kotecha a, Darren R. Feldman a ‡, Robert J. Motzer a ‡
Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial
Fredrik Möller a b, Marianne Månsson a, Jonas Wallström c d, Mikael Hellström c d, Jonas Hugosson a e, Rebecka Arnsrud Godtman a e
Prostate-specific Antigen Screening in Limbo: How Low Should We Go?
Ian M. Thompson Jr. a b *
Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial
Jeremy Yuen-Chun Teoh a b , Cheung-Hing Cheng c d , Chiu-Fung Tsang e f , Joseph Kai-Man Li a b , Bryan Kwun-Chung Cheng g h , Wilson Hoi-Chak Chan g h , Wayne Kwun-Wai Chan i j , Trevor Churk-Fai Li k , Yi Chiu l , Man-Chung Law m , Clarence Lok-Hei Leung i j , Brian Sze-Ho Ho e f , Chris Yue-Kit Lee c d , Ronald Cheong-Kin Chan n , Eddie Shu-Yin Chan a , Marco Tsz-Yeung Chan c d , James Hok-Leung Tsu e f , Ho-Man Tam a b , Kin-Man Lam g h , Hing-Shing So g h … Chi-Fai Ng a b
Can an En Bloc Technique Improve Outcomes of Endoscopic Surgery for Non–muscle-invasive Bladder Cancer?
Marko Babjuk
Single-cell Atlas of Penile Cancer Reveals TP53 Mutations as a Driver of an Aggressive Phenotype, Irrespective of Human Papillomavirus Status, and Provides Clues for Treatment Personalization
Laura Elst a b c, Gino Philips a, Kaat Vandermaesen a b c, Ayse Bassez a, Francesca Lodi a, Manon T.A. Vreeburg d, Oscar R. Brouwer d, Rogier Schepers a, Thomas Van Brussel a, Sambit K. Mohanty e f, Anil V. Parwani g, Lien Spans h, Isabelle Vanden Bempt h, Gerd Jacomen i, Marcella Baldewijns j, Diether Lambrechts a †, Maarten Albersen b c â€
TP53Â Mutations Emerge as a Critical Biomarker in Penile Cancer, Superseding Human Papillomavirus Status
Jad Chahoud a, Xiaoqing Yu b, Andrea Necchi c d, Philippe E. Spiess a
Current Standards for Training in Robot-assisted Surgery and Endourology: A Systematic Review
Giuseppe Basile a b †, Andrea Gallioli a c †, Pietro Diana a c d, Anthony Gallagher e f g, Alessandro Larcher b, Markus Graefen h, Nina Harke i, Olivier Traxer j, Derya Tilki h k l, Henk Van Der Poel m, Esteban Emiliani a, Oriol Angerri a, Christian Wagner n, Francesco Montorsi b, Peter Wiklund o p, Bhaskar Somani q, Nicolò Buffi d, Alex Mottrie g r, Evangelos Liatsikos s, Alberto Breda a c
Insights into Training Standards for Robot-assisted Surgery and Endourology: A Perspective for Both Urologists and Trainees
Nicholas Raison a , Prokar Dasgupta c , Thomas Knoll b
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent
Philip Cornford a , Roderick C.N. van den Bergh b , Erik Briers c , Thomas Van den Broeck d , Oliver Brunckhorst e , Julie Darraugh f , Daniel Eberli g , Gert De Meerleer h , Maria De Santis i j , Andrea Farolfi k , Giorgio Gandaglia l m , Silke Gillessen n o , Nikolaos Grivas p , Ann M. Henry q , Michael Lardas r , Geert J.L.H. van Leenders s , Matthew Liew a , Estefania Linares Espinos t , Jan Oldenburg u v , Inge M. van Oort w … Derya Tilki jj kk ll
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Derya Tilki a b c, Roderick C.N. van den Bergh d, Erik Briers e, Thomas Van den Broeck f, Oliver Brunckhorst g, Julie Darraugh h, Daniel Eberli i, Gert De Meerleer j, Maria De Santis k l, Andrea Farolfi m, Giorgio Gandaglia n o, Silke Gillessen p q, Nikolaos Grivas r, Ann M. Henry s, Michael Lardas t, Geert J.L.H. van Leenders u, Matthew Liew v, Estefania Linares Espinos w, Jan Oldenburg x y, Inge M. van Oort z…Philip Cornford v
Re: EV-301 Long-term Outcomes: 24-month Findings from the Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Advanced Urothelial Carcinoma
Marcus J. Drake a, Lori A. Birder b
Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression
Marie-Pier St-Laurent, Peter C. Black
Re: Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
Markus Grabbert, Nikolaos Liakos, Christian Gratzke
Re: Robot-assisted Radical Cystectomy with Totally Intracorporeal Urinary Diversion Versus Open Radical Cystectomy: 3-year Outcomes from a Randomized Controlled Trial
Stefano Mancon a b , Heidemarie Ofner c , David D'Andrea c
Re: External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort
Christian D. Fankhauser a b, Marian S. Wettstein c, Christoph Würnschimmel a, Maarten van Smeden d, Noel W. Clarke e f
Re: Stereotactic Ablative Body Radiotherapy for Primary Kidney Cancer (TROG 15.03 FASTRACK II): A Non-randomised Phase 2 Trial
Aimin Jiang a †, Ying Liu a †, Chen Cai b †, Peng Luo c †, Linhui Wang a
Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer
Nicholas G. Nickols a b c, Sonny Tsai a, Nathanael Kane a b, Samantha Tran a, Leila Ghayouri a, Silvia Diaz-Perez a b, May Thein d, Nancy Anderson-Berman d, Jeanie Eason e, Amar U. Kishan b c, Michael L. Steinberg b c, Robert E. Reiter c, Steve P. Lee d, Greg E. Gin d, Robert Kwon d, Michael G. Chang e, Hann-Hsiang Chao e, Abhiskek A. Solanki f, Rachael Sexton g, Michael Lewis a…Matthew B. Rettig a c h
Re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68
Giancarlo Marra , Marco Oderda , Paolo Gontero
Reply to Giancarlo Marra, Marco Oderda, Paolo Gontero, and Lorenzo Richiardi’s Letter to the Editor re: Jim C. Hu, Melissa Assel, Mohamad E. Allaf, et al. Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial. Eur Urol. 2024;86:61–68
Jim C. Hu a, Mohamad E. Allaf b, Andrew J. Vickers c, Edward M. Schaeffer d
Re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. 2024;85:e162–e163
Behnam Shakiba a b c *
Reply to Behnam Shakiba’s Letter to the Editor re: Emilien Seizilles de Mazancourt, Juliette Cotte, Caroline Plassais, et al. Sexual and Moral Harassment of French Urologists in Training and Barriers to Reporting: Results from a National Survey. Eur Urol. 2024;85:e162–e163
Emilien Seizilles de Mazancourt a , Kevin Kaulanjan b
Re: David Musheyev, Alexander Pan, Stacy Loeb, Abdo E. Kabarriti. How Well Do Artificial Intelligence Chatbots Respond to the Top Search Queries About Urological Malignancies? Eur Urol 2023;85:13–6
Qi-Fei Deng a †, Yuan-Yuan Bao b †, Yuan-Yuan Yang b , Chang-Kun Mao a
Re: Thomas Powles, Zoe June Assaf, Viraj Degaonkar, et al. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma. Eur Urol 2024;85:114–22
Viria Beccia a, Giada Pinterpe b, Roberto Iacovelli a c
Re: Michael Eppler, Conner Ganjavi, Lorenzo Storino Ramacciotti, et al. Awareness and Use of ChatGPT and Large Language Models: A Prospective Cross-sectional Global Survey in Urology. Eur Urol 2024;85:146–53
Chao-Yang a , Yuan-Yuan Bao b , Yuan-Yuan Yang b , Chang-Kun Mao a
Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur Urol. 2024;85:565–573
Olivier Cussenot a b, Antoine Chambaz c, Freddie C. Hamdy a
